Detalhe da pesquisa
1.
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
N Engl J Med
; 375(8): 740-53, 2016 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27292104
2.
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
Cancer
; 124(8): 1722-1732, 2018 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29381191
3.
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Lancet Oncol
; 11(2): 129-35, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20036194
4.
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Clin Cancer Res
; 27(10): 2742-2754, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33602684
5.
Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
Int J Hematol
; 110(6): 709-722, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31655984
6.
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
J Drug Assess
; 6(1): 10-17, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28959500
7.
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Clin Cancer Res
; 22(19): 4807-4816, 2016 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27154915
8.
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
Cancer Chemother Pharmacol
; 65(4): 765-73, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19649631
9.
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.
J Clin Oncol
; 26(19): 3196-203, 2008 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18474873